Funding for this research was provided by:
Seventh Framework Programme (HEALTH-F2–2014–60246)
Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (MDC)
Received: 6 October 2020
Accepted: 17 May 2021
First Online: 5 June 2021
: The study protocol was approved by the local ethics committees (Ethikkommission Charité Universitätsmedizin Berlin, Reference No. EA2/092/14 and Medisch Ethische Toetsingscommissie, Universitair Medisch Centrum Utrecht, Reference No. 14–469). Assessments complied with the Declaration of Helsinki. All participants scored ≥24 on the Mini Mental State Examination (a screening instrument for dementia) and were capable of giving full written informed consent to participate.
: Not applicable.
: GW is coordinator of the BioCog consortium and is chief executive of the company Pharmaimage Biomarker Solutions GmbH (ExternalRef removed). Among other academic and private partners, the company is a partner of the BioCog study. CS and TP are project leaders in BioCog. IF, PK, FB, SM, JK, CS and TP declare that they have no conflicts of interest.